Operating Income (Loss) in USD of MiNK Therapeutics, Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
MiNK Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2020 to Q3 2025.
  • MiNK Therapeutics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$3.18M, a 68.9% decline year-over-year.
  • MiNK Therapeutics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$12.4M, a 12.9% increase year-over-year.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$11.3M, a 50.8% increase from 2023.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$22.9M, a 25.9% increase from 2022.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$30.9M, a 9.14% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

MiNK Therapeutics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$12.4M -$3.18M -$1.3M -68.9% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$11.1M -$4.05M -$981K -32% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$10.2M -$2.7M +$1.13M +29.5% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 -$11.3M -$2.5M +$3M +54.5% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025
Q3 2024 -$14.3M -$1.88M +$3.34M +63.9% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$17.6M -$3.07M +$3.27M +51.6% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$20.9M -$3.83M +$2.02M +34.6% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$22.9M -$5.5M +$2.39M +30.3% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025
Q3 2023 -$25.3M -$5.22M +$2.76M +34.6% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$28.1M -$6.34M +$1.36M +17.6% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$29.4M -$5.85M +$1.52M +20.6% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024
Q4 2022 -$30.9M -$7.89M -$1.53M -24% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024
Q3 2022 -$29.4M -$7.99M +$5.39M +40.3% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 -$34.8M -$7.7M -$2.09M -37.2% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$32.7M -$7.37M -$4.37M -145% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$28.4M -$6.36M 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023
Q3 2021 -$13.4M -$7.45M -126% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$5.61M 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$3.01M 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022
Q3 2020 -$5.92M 01 Jul 2020 30 Sep 2020 10-Q 29 Nov 2021

MiNK Therapeutics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$11.3M +$11.6M +50.8% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025
2023 -$22.9M +$8.03M +25.9% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025
2022 -$30.9M -$2.59M -9.14% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024
2021 -$28.4M -$13.7M -93.7% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023
2020 -$14.6M 01 Jan 2020 31 Dec 2020 10-K 18 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.